New Hope for High-Risk Prostate Cancer – Promising Immunotherapy Agent Proven To Be Safe
According to a phase 2 study conducted by the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, the monoclonal antibody enoblituzumab…